Amit Kumar, Chief Executive Officer at Anixa Biosciences Inc (ANIX), bought 7,000 shares at $2.78 ($19K) on 2026-09-24, disclosed to the SEC on 2026-09-28.
Anixa Biosciences CEO Amit Kumar purchased 7,000 shares for $19,460 on September 24, 2026, signaling confidence in the company's oncology pipeline and recent analyst upgrades. This insider buying comes as the stock trades near its 52-week low, potentially offering a contrarian entry point.
The stock is down 20.0% over the last 30 days and is currently trading 17.3% above its 52-week low of $2.37, despite a 2.58% gain in the past five days.
1) Zacks upgraded ANIX to a Strong Buy (Zacks Rank #1) on July 22, 2026. 2) The company views 2026 as a 'pivotal year' for its breast cancer vaccine and CAR-T therapies, per CEO comments on February 10, 2026. 3) A new Korean patent for the breast cancer vaccine was secured on June 30, 2026.
The stock is down 18.24% over the last year and is currently trading 49.05% below its 52-week high of $5.4566, indicating significant historical volatility and recent underperformance.
Something here stands out, but not much.
| Filing → |
| ANIX | BUY | 2026-08-03 | $17K | — | Filing → |
| ANIX | BUY | 2026-07-28 | $17K | — | Filing → |
| ANIX | BUY | 2026-07-27 | $11K | — | Filing → |